Sesen Bio — Corporate Update (May 2020)
68 slides from Sesen Bio's corporate update, May 11, 2020
Slide 1: May 2020 Business Update
May 2020 Business Update For Investor Purposes Only May 11, 2020 NASDAQ: SESN
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical devel
Slide 3: Monitoring and mitigating potential risks across critical business areas
We are monitoring and mitigating potential risks across critical business areas No business disruptions from COVID-19 at this time Clinical • Patient enrollment was completed in March 2018 • All patients have completed treatment in the VISTA trial • Last data cut was done in May 2019 • All clinical
Slide 4: May 2020 Business Update
MAY 2020 BUSINESS UPDATE • Highly differentiated mechanism of action and clinical profile • Market research supports large commercial opportunity • Positive data demonstrates meaningful progress for CMC comparability • Clear regulatory path forward 4
Slide 5: Patient journey in bladder cancer
BLOOD IN URINE See PCP; therapeutic trial of antibiotics prescribed IN BLADDER CANCER, THE Still see blood in urine See UROLOGIST GUIDES THE PATIENT blood in urine; try different antibiotic Confusion and concern on problem JOURNEY Begin tests REFERRED TO Shock and UROLOGIST st CT Scan emotional Prep
Slide 6: Vicinium has a Highly Differentiated Mechanism of Action
Vicinium has a Highly Differentiated Mechanism of Action Mechanism 1: Mechanism 2: Kills cell directly Activates immune system Vicinium selectively targets EpCAM on T cells recognize neoantigen cancer cells while and kill cancer cells generally leaving healthy cells alone Vicinium causes immunogenic
Slide 7: 1Q 2020 Intent-to-Prescribe Market Research Results
1Q 2020 Intent-to-Prescribe Market Research Results We conducted 30-minute interviews with 34 high- prescribing Urologists to assess their views of the Vicinium profile vs. the Keytruda profile based on available clinical information For investor purposes only 7
Slide 8: Market Research Input: Clinical Data from Emerging Treatments for NMIBC
Market Research Input Clinical Data from Emerging Treatments for NMIBC Vicinium Profile Keytruda Profile Efficacy N=89 N=102 Complete Response Rate • At 3 Months 40% (CI: 30-51) 41% (CI: 32-51) • At 12 Months 17% 20% • At 18 Months 11% 13% 76% of patients were cystectomy-free Time to Cystectomy No d
Slide 9: High Prescribing Urologists Prefer Vicinium Profile
1Q 2020 Market Research Results High Prescribing Urologists Prefer Vicinium Profile Intent-to-Prescribe Key Attributes (Stated share of branded agents)* Extremely 10.0 90% 83% 9.0 8.6 80% 8.2 8.2 8.0 70% 7.0 6.2 60% 6.0 5.8 5.4 5.2 50% 5.0 40% Average RatingAverage 4.0 % of patients % of 3.4 30% 3.0
Slide 10: Reasons Urologists Prefer Vicinium Profile
1Q 2020 Market Research Results Reasons Urologists Prefer Vicinium Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perceiv
Slide 11: Meaningful Progress on Demonstrating Analytical Comparability
Meaningful Progress on Demonstrating Analytical Comparability We have maintained high-quality manufacturing standards through tech transfer process to Fuji Sesen Fuji GMP Run Pre-PPQ Run Test Phase II Phase III 2Q 2019 1Q 2020 Appearance 9 9 9 9 pH 9 9 9 9 Identity 9 9 9 9 Concentration 9 9 9 9 Poly
Slide 12: Analytical Comparability Outlook
Analytical Comparability Outlook Clear FDA requirements for the PPQ Campaign • Three manufacturing runs for both drug substance and drug product Considerable in-house manufacturing process expertise from clinical manufacturing • Successfully manufactured 10 drug substance and 12 drug product batches
Slide 13: US Regulatory Path Forward
US Regulatory Path Forward Key CMC activities in 2020 are designed to demonstrate analytical comparability between commercial and clinical supply for the finalization of the BLA submission 2019 2020 2021 4Q 1Q 2Q 3Q 4Q 1Q 2Q Initiated BLA Finalize BLA Potential approval submission submission CMC Pre
Slide 14: Positive Interactions with EMA on Regulatory Pathway for Vicinium
Positive Interactions with EMA on Regulatory Pathway for Vicinium The CHMP issued guidance on the regulatory pathway for Vicinium: • The nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a MAA submission for Vicinium and additional clinical trials were
Slide 15: Highly Concentrated Prescriber Base Allows for Efficient Commercial Model
Highly Concentrated Prescriber Base Allows for Efficient Commercial Model aRI8URORJ\SUDFWLFHVKDYH•8URORJLVWV1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients % of Patients 50% 40% 30% 20% 10% 0% 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 2,200 2,400
Slide 16: Educating caregivers via digital and social channels
At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • PPaid search • OOrganic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups • T
Slide 17: Pricing and Reimbursement
Pricing and Reimbursement US Benchmarks Price Reference Payer Management Responses (Annual Cost) to Pricing2 100% $200K Anticipated Keytruda1 competitive pricing $150K 50% Proportion of Payers of Proportion $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA to Label Key: PA to Trial Ris
Slide 18: Financial Overview as of March 31, 2020
Financial Overview as of March 31, 2020 Cash position • Ending cash and cash equivalents of $42.5M • Sufficient cash to fund key strategic priorities into 2021 ATM • 4Q 2019: net proceeds of $1.9M (2.1M shares) • 1Q 2020: net proceeds of $3.2M (3.2M shares) Capital structure • 110 M shares of common
Slide 19: May 2020 Summary
MAY 2020 SUMMARY • Highly differentiated mechanism of action and clinical profile • Market research supports large commercial opportunity • Positive data demonstrates meaningful progress for CMC comparability • Clear regulatory path forward 19
Slide 20: Talented and Experienced Leadership Team Prepared for Commercial Launch
Talented and Experienced Leadership Team Prepared for Commercial Launch Senior Management Board of Directors Omar Rifi Thomas Cannell, DVM Jay Duker, M.D. Vice President, Business Development President, CEO and Director Chair of the Board of Directors and Alliance Management Monica Forbes Louise Ste
Slide 21: Appendix - Table of Contents
Appendix - Table of Contents Section Slide number Patient Journey 22-23 Unmet Medical Need 24-27 Dual Mechanism of Action 28-30 Regulatory 31-36 Clinical Data 37-55 Commercial Opportunity 56-61 Manufacturing & Supply Chain 62-66 Intellectual Property 67-68 For Investor Purposes Only 21
Slide 22: Appendix: Patient Journey
Appendix Patient Journey 22
Slide 23: Bladder cancer patient experience is among the poorest
Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who Had Experience Who Had Patients % of 2
Slide 24: Appendix: Unmet Medical Need
Appendix Unmet Medical Need 24
Slide 25: Significant Unmet Medical Need in NMIBC
Significant Unmet Medical Need in NMIBC ~440,000 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 new cases each year globally1 Bladder cancer is the most expensive cancer to treat in the US with projected costs of ~$6B by 20204 One of the worst patient experie
Slide 26: Vicinium is cystectomy-sparing
Our Phase III data suggests Vicinium is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery ƒ Self-controlled storage organ in ƒ Often a 10 hour or longer surgery the body ƒ In women, removal of t
Slide 27: Latest global BCG shortage expected to last through 2020
Latest global BCG shortage expected to last through 2020 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints of BCG Tice strain
Slide 28: Appendix: Dual Mechanism of Action
Appendix Dual Mechanism of Action 28
Slide 29: Vicinium is Highly Differentiated and has a Dual Mechanism of Action
Vicinium is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr
Slide 30: High somatic mutation rate in bladder cancer may improve response
The high somatic mutation rate in bladder cancer may lead to a better response to agents such as Vicinium that may stimulate T cell-mediated immune activation driven by neoantigens Adapted from Zahir et al. Nature Medicine, 2017 30
Slide 31: Appendix: Regulatory
Appendix Regulatory 31
Slide 32: Clinical program aligned with FDA guidance
Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models 9 • Conduct nonclinical studies to demonstrate anti-tum
Slide 33: Strong benefit-risk profile in Phase III Trial
Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp
Slide 34: Initiation of Vicinium BLA submission under Rolling Review
Initiation of Vicinium BLA submission under Rolling Review on December 6, 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission 82% As part of a compr
Slide 35: Significant Progress in 2019
Significant Progress in 2019 4 Pivotal Face-to-Face Meetings Led to BLA Submission of Clinical/Nonclinical Data 9 May 2019: FDA Accepts CMC Analytical Comparability Plan • No additional clinical trials deemed necessary at this time, subject to final review of comparability data in the BLA 9 June 201
Slide 36: Key Elements of BLA Submission for Vicinium
Key Elements of BLA Submission for Vicinium We initiated our BLA submission under Rolling Review on December 6th 2019 and believe this significantly de-risks the regulatory path to approval Module 1 Module 2 Module 3 Module 4 Module 5 ¾ General corporate ¾ Introduction to summary ¾ Drug substance ¾
Slide 37: Appendix: Clinical Data
Appendix Clinical Data 37
Slide 38: Phase III Trial: Patient Demographics
Phase III Trial: Patient Demographics COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months PRQWKVEXW”PRQWKVRI CIS) that that recurred of adequate BCG adequate BCG within 6 months of adequate BCG Total pat
Slide 39: Vicinium has a Highly Differentiated Clinical Profile
Vicinium has a Highly Differentiated Clinical Profile Efficacy Data Safety Data 3 month response data Intravesical administration • CIS: 40% complete response rate • Bladder wall serves protective function • Papillary: 71% recurrence-free rate • Preference of FDA* and most Urologists Durability of r
Slide 40: Compelling Clinical Data Set
Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95% CI rules out clinically unmeaningful CRR disease, or disease progres
Slide 41: Additional Vicinium Clinical Data: CIS Patients
PII & PIII Additional Vicinium Clinical Data CIS Patients Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-mon
Slide 42: Phase III Evaluable Patient Data Tables by Cohort
Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 17%
Slide 43: Complete and Partial Response
Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response 3-Month3-Month Responsep 40% of patients had a complete response Start ofof TTreatmentreatment with 43% of patientspatients had a partialpartial responseresponse VViciniumicinium 17% of
Slide 44: Duration of Response
Duration of Response: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40 % of Patients wit
Slide 45: Duration of Response: Probability of Remaining Cancer-Free
Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free Probability of Maintaining Complete Response (CR) for at Least One Additional Year* CR at 12 months 74% CR at 9 months 61% CR at 6 months 56% CR at 3 months 42% Day 0 17% 0% 20% 40% 60%
Slide 46: Vicinium more efficacious in CIS patients treated with less BCG
Duration of Response: Vicinium is generally more efficacious in CIS patients treated with less BCG The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations •%&*LQVWLOODWLRQV 80 X Censored 60 Median 40 20 % of Patients with Complete Response Comp
Slide 47: Time to Disease Recurrence
Time to Disease Recurrence: Time to Disease-Recurrence: 50% of high-risk papillary patients who were treated with Vicinium are disease-free at 1 year Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored 95% CI 60 50% 40 37% % of Patients
Slide 48: Recurrence-free Rate
Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-months n=38 4
Slide 49: Highly Differentiated Time-to-Cystectomy Data
Highly Differentiated Time-to-Cystectomy Data vs. Currently Available Agents 76% of patients are cystectomy-free for 3 years No patient on treatment progressed to metastatic disease 100 Legend: KM Estimate X Censored 80 95% CI 60 Median 40 20 % of Patients Cystectomy-Free Patients % of 0 0 3 6 9 12
Slide 50: Time to Cystectomy: Responders vs Non-responders
Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 Statistically significant difference for 80 responders vs. non-responders: p = < 0.001
Slide 51: Safety and Tolerability: Phase II and Phase III
Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Treatment-related serious adverse Patient
Slide 52: No age-related increase in adverse events
Safety and Tolerability: No age-related increase in adverse events in our Phase III trial The average patient in the VISTA trial was ~74 years old 10 Adverse Events 9.0 Treatment-related Adverse Events 7.9 8 7.5 6 4 3.0 Mean AEs/patient Mean 2.1 2 1.6 0 54-69 70-79 80+ (n=40) (n=57) (n=36) Age (year
Slide 53: Market Research Input: Profile of Emerging Treatments for NMIBC
Market Research Input Profile of Emerging Treatments for NMIBC Keytruda Profile Vicinium Profile Binds to the PD-1 receptor, blocking both PD-L1 and Selectively targets and kills bladder cancer cells while Mechanism of Action PD-L2 from interacting with PD-1 to help restore T cell- sparing healthy c
Slide 54: 3-month complete response rate data from different clinical trials
3-month complete response rate data from different clinical trials Please use caution when drawing comparisons across different clinical trials Vicinium 3-month CRR Keytruda 3-month CRR 60 60 U.S. Patients1 Overall1 Overall3 53% U.S. Patients3 50 51% 50 51% 48% 40 40% 41% 40 41% 32% 31% 30 30% 29% 3
Slide 55: Pipeline of Targeted Therapies
Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicinium in combination with checkpoint inhibitors. Vicinium in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 trial run by the National Cancer Institute. PRODUCT CAND
Slide 56: Appendix: Commercial Opportunity
Appendix Commercial Opportunity 56
Slide 57: Virtuous Cycle: physicians, patients and payers as advocates
Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo
Slide 58: Large Global Commercial Opportunity
Large Global Commercial Opportunity Substantial US opportunity and OUS potential of 2-3 times the US • We have CMO partners capable of reliably meeting that demand Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after
Slide 59: Vicinium has the Potential to Provide Continuity of Care for NMIBC
Vicinium has the Potential to Provide Continuity of Care for Patients with NMIBC Checkpoint Treatment Protocol BCG Vicinium Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X
Slide 60: Addressable Market (US)
Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~40% - 80% of BCG treatments fail or disea
Slide 61: OUS opportunity for Vicinium is 2-3 times larger than the US
We estimate the OUS opportunity for Vicinium is 2-3 times larger than the US Geography Est. Incidence Relative to U.S.1 Est. Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not
Slide 62: Appendix: Manufacturing & Supply Chain
Appendix Manufacturing & Supply Chain 62
Slide 63: Reliable and Inexpensive Manufacturing Process
Reliable and Inexpensive Manufacturing Process Vicinium is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-good
Slide 64: Reliable and Inexpensive Manufacturing Process
Reliable and Inexpensive Manufacturing Process 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ IMAC
Slide 65: Experienced Partners for Global Manufacturing and Supply of Vicinium
We have Experienced Partners for the Global Manufacturing and Supply of Vicinium ¾ Licensed for commercial production of 8 approved products ¾ 25+ years developing and manufacturing biologics ¾ 310+ protein-based therapeutics in development and/or manufacturing ¾ Proven track record with FDA and wor
Slide 66: Vicinium Commercial Manufacturing Strategy
Vicinium Commercial Manufacturing Strategy Clinical Supply Commercial Supply Drug Substance Sesen Fuji (CMO) Drug Product Sesen Baxter (CMO) The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characte
Slide 67: Appendix: Intellectual Property
Appendix Intellectual Property 67
Slide 68: Vicinium Patent Life
Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (May 2020 - July 2020) US: 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Meth